Podcasts about jacc

In this episode of JACC This Week, Dr. Harlan M. Krumholz and Dr. Carolyn S.P. Lam discuss a dedicated issue of JACC focused on cardiac amyloidosis—one of the fastest-evolving areas in cardiovascular medicine. They explore new evidence highlighting significant delays in diagnosing ATTR cardiomyopathy, the early divergence of mortality benefit with timely treatment, and why time to diagnosis is no longer a neutral factor. The conversation also examines secondary analyses from major clinical trials, practical guidance for amyloidosis evaluation and management, and Dr. Krumholz's Editor's Page on "computable diagnosis" as a moral imperative. This episode places emerging science in clinical context, emphasizing urgency, equity, and how clinicians should be thinking differently about diagnosis, staging, and access to therapy in amyloid heart disease. Read Full issue here: https://www.jacc.org/toc/jacc/87/5 Keywords: cardiac amyloidosis, amyloid heart disease, ATTR cardiomyopathy, computable diagnosis

Welcome to the new season of JACC This Week! In this episode, Editor-in-Chief Dr. Harlan Krumholz is joined by co-host Dr. Carolyn Lam to kick off a refreshed, more conversational era of the podcast. Together, they reflect on the evolution of the show, approach to thematic curation, and introduce the February 3 issue of JACC, curated around valve heart disease. The discussion explores JACC's approach to thematic issues, the importance of timely publication, and how emerging evidence is shifting valvular heart disease management toward lifetime decision-making and patient-centered outcomes. Highlights include insights into aortic stenosis and regurgitation, tricuspid regurgitation, global perspectives on valve care, and what clinicians should be watching as transcatheter therapies continue to evolve. Dr. Krumholz also shares the thinking behind his Editor's Page on scientific writing—specifically, how a strong introduction earns the reader's trust—offering practical guidance for researchers at all stages. The episode sets the tone for a new season focused on rigor, relevance, global inclusion, and meaningful dialogue with the cardiovascular community.

Peripheral artery disease has been called the ‘silent circulatory crisis'—affecting millions, limiting mobility, and quietly raising the risk of heart attack, stroke, and limb loss. For decades, treatment focused on walking programs, aspirin, and sometimes a stent or bypass. But today, the landscape is changing. From PCSK9 inhibitors that drive cholesterol to record lows, to GLP-1 agonists like semaglutide improving walking distance, to novel antithrombotic strategies that balance bleeding and clotting—PAD care is entering a new era. In this episode, we'll explore the breakthroughs, the evidence behind them, and what they mean for patients who just want to keep moving forward." Hosted by the University of Michigan Department of Vascular Surgery: - Robert Beaulieu, Program Director - Frank Davis, Assistant Professor of Surgery - Luciano Delbono, PGY-5 House Officer - Andrew Huang, PGY-4 House Officer - Carolyn Judge, PGY-2 House Officer Learning objectives:  1.  Describe the current evidence-based recommendations for multifactorial medical management of peripheral artery disease (PAD), including lipid, glycemic, and antithrombotic strategies per 2024 SVS/AHA guidelines.  2. Interpret the clinical implications of the FOURIER trial regarding the role of PCSK9 inhibition in reducing cardiovascular events in patients with atherosclerotic disease, including PAD.  3.  Evaluate the emerging role of GLP-1 receptor agonists, such as semaglutide, in improving walking performance and quality of life among patients with diabetic PAD based on findings from the STRIDE trial. Sponsor URL: https://www.goremedical.com/ References:  H. L. Gornik et al., “2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease,” JACC, vol. 83, no. 24, pp. 2497–2604, June 2024, doi: 10.1016/j.jacc.2024.02.013. L. Mazzolai et al., “2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM),” Eur Heart J, vol. 45, no. 36, pp. 3538–3700, Sept. 2024, doi: 10.1093/eurheartj/ehae179. https://pubmed.ncbi.nlm.nih.gov/40169145/ M. S. Sabatine et al., “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease,” N Engl J Med, vol. 376, no. 18, pp. 1713–1722, May 2017, doi: 10.1056/NEJMoa1615664. https://pubmed.ncbi.nlm.nih.gov/28304224/ M. P. Bonaca et al., “Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial,” Lancet, vol. 405, no. 10489, pp. 1580–1593, May 2025, doi: 10.1016/S0140-6736(25)00509-4. https://pubmed.ncbi.nlm.nih.gov/40169145/ N. E. Hubbard, D. Lim, and K. L. Erickson, “Beef tallow increases the potency of conjugated linoleic acid in the reduction of mouse mammary tumor metastasis,” J Nutr, vol. 136, no. 1, pp. 88–93, Jan. 2006, doi: 10.1093/jn/136.1.88. https://pubmed.ncbi.nlm.nih.gov/16365064/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Effect of Empagliflozin on Whole Body, Cardiac, and Renal Sympathetic Outflows in Type 2 Diabetes.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Differences in Severity and Prognosis Between Bicuspid and Tricuspid Severe Aortic Stenosis.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in the Clinical Recognition of Significant Aortic Stenosis.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Cardiovascular-Kidney-Metabolic Syndrome-Attributable Mortality in the United States, From 2010 to 2023.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Long-Term Survival in Liver Transplant Patients With Coronary Artery Disease: A Multi-Institutional Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Association of Atrial Fibrillation Symptom Burden With Social Determinants of Health.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on FGF-23, hsCRP, Cardiovascular Events, and the Benefit of Canagliflozin in the CANVAS Trial.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Ivabradine and Atrial Fibrillation Incidence: A Nested Matching Study.

In this week's episode of Parallax, Dr Ankur Kalra welcomes Prof Rasha Al-Lamee, interventional cardiology consultant and professor of medicine/cardiology at Imperial College London, and deputy editor of JACC. Prof Al-Lamee has transformed interventional cardiology through her pioneering work on the ORBITA trial series and coronary sinus reducer device studies, introducing the paradigm-shifting concept of sham-controlled device trials to the field. What makes a clinical assumption worth questioning? How do we design trials that reveal truth rather than confirm bias? When does revascularization truly benefit patients with stable angina? Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Guest: @RashaAlLameeMD Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

In the 200th episode of Health & Veritas, Harlan offers end-of-the-year reflections on medicine drawn from his editor's notes in JACC (the Journal of the American College of Cardiology), and Howie provides updates on gun violence, flu, measles, and the health benefits of yoga. Show notes: Editor's notes by Harlan Krumholz "The Day I Became a Doctor" "When Your Patient Dies" "Rethinking Physician Certification: A Call for a Modern, Meaningful Standard" Gun violence, flu, and measles "Mass shootings outnumber annual days in U.S., children are missing school due to measles, Covid-19 is peeping around the corner, and some hope" "Measles outbreaks worsen in South Carolina, Arizona and Utah" "Connecticut reports first measles case in years" "New Flu Variant May Be Triggering Spike in Severe Disease" "High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults" "Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance" The benefits of yoga "Yoga for chronic non‐specific low back pain" "Yoga-based interventions may reduce anxiety symptoms in anxiety disorders and depression symptoms in depressive disorders: a systematic review with meta-analysis and meta-regression" "Effect of Yoga on Frailty in Older Adults" "Yoga in autoimmune disorders: a systematic review of randomized controlled trials" "Long-term effects of yoga-based practices on neural, cognitive, psychological, and physiological outcomes in adults: a scoping review and evidence map" "Yoga isn't just for flexibility. It may also protect brain health." In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Introduction by Dr. Bonnie Ky.

Audio Summary of the December 2025 Issue by Dr. Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Pilar Martin.

Commentary by Dr. Avirup Guha.

Commentary by Dr. Eric Yang.

Commentary by Dr. Peter van der Meer.

Commentary by Dr.  Rungroj Krittayaphong.

Commentary by Dr.  Martin Bergmann.

Commentary by Dr.  Eue-Keun Choi.

The U.S. heart failure landscape is transforming—and fast.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Gender Differences in Barriers to Academic Cardiovascular Careers in North America.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Prognostic Implications of Preoperative hs-cTnT in Elective Coronary Artery Bypass Grafting.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Multicenter Prospective Assessment of Coronary Microvascular Dysfunction: Primary Results of the FlowLab Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Unfavorable Social Determinants of Health and Obesity: A Double Jeopardy for Premature Mortality.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Long-Term Implantable Cardioverter Defibrillator Lead Dysfunction After Left Ventricular Assist Device Implantation.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Educational Attainment as the Primary Socioeconomic Determinant of Heart Failure: A Multivariable Mendelian Randomization Study.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Elevated Lipoprotein(a) Independently Increases Risk for Short-Term Atherosclerotic Cardiovascular Events in Machine Learning Predictive Models.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Predictive Models Aid Prognostication: Secondary Analysis Integrating Model and Physician Prognostic Estimates in Heart Failure.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Lipoprotein(a) Testing Trends in the United States 2015-2024: An Analysis of 300 Million Individuals.

In the December 2, 2025 episode of JACC This Week, Editor-in-Chief Harlan M. Krumholz, MD, SM, introduces the Spotlight Issue, anchored by the manuscript "Global, Regional, and National Burden of Cardiovascular Disease and Risk Factors in 204 Countries and Territories, 1990–2023." Listen here as he reviews the issue and gives listeners perspective on the issue as a whole, which contains 19 viewpoints providing perspectives from experts around the world, plus his editor's page, aligned with a talk given at the UN with JACC Editor Emeritus Valentin Fuster, MD, and author Gregory A. Roth, MD. Other perspectives include: CVD in Sub-Saharan Africa; access to essential medicines and technologies; confronting inequities in pediatric cardiac care; and perspectives from Japan, Canada, the Middle East & North Africa, South America, Pakistan, and many others.  Listen to the podcast and then check out the full issue online here: https://www.jacc.org/toc/jacc/86/22.

https://www.tadeclinicagem.com.br/guia/?utm_source=whatsapp&utm_medium=social&utm_term=&utm_content=&utm_campaign=Guia-blackfriday&utm_source_platform=&utm_creative_format=&utm_marketing_tactic=

Commentary by Dr. Jian'an Wang.

Commentary by Dr.  Jian'an Wang.

JACC's November 25, 2025 issue kicks off Thanksgiving week with JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, reflecting on his editor's page and the day he became a doctor (0:12).  For original research articles, he discusses a study on colchicine & clonal hematopoiesis, an exploratory study of the LoDoCo2 trial (1:10), and a paired editorial comment with more perspectives and a reminder of the upcoming COLCOT trial (4:33). Next, a study on Lp(a) and IL-6 (4:54) and an editorial (6:12), 30-year CVD risk percentiles based on the PREVENT equations (6:30), and an accompanying editorial from JACC Deputy Editor Erica Spatz, MD, on next-generation strategies to encourage healthier behaviors (7:35).  Other studies and editorials include a fascinating look at alcohol and blood pressure (8:04) and reinforcing the WHO public health guidance (10:05); remnant cholesterol in young adults (10:38) and implications for cholesterol guidelines (12:36). We also include four brief reports on RSV vaccine (13:11), long Covid (13:43), Lp(a) levels (14:06), the predictive power of polygenic risk scores (14:58), a viewpoint on US veterans (15:36), and our regular Amara Yad image (15:53), which we're delighted to be able to continue to promote with JACC: Clinical Electrophysiology Editor-in-Chief Kalyanam Shivkumar, MD.  

In the November 18, 2025 issue of JACC, Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, uses his editor's page to reflect on the evolving role of editors as partners with authors in strengthening cardiovascular science. The issue itself centers on adiposity, featuring multiple pooled analyses showing that waist-to-height ratio and waist circumference outperform BMI in predicting heart failure and mortality risk. Other highlights include a meta-analysis confirming GLP-1 receptor agonists' broad cardiovascular benefits, new insights into obesity's impact on biomarkers and disease interpretation, and several pieces, including state of the art reviews and viewpoints, on obesity-related conditions. Our issue focus on adiposity as a central driver of cardiometabolic disease shows the need for tailored, collaborative approaches to patient care and research. #stride #adipokinehypothesis

In this week's JACC podcast, Editor-in-Chief Dr. Harlan Krumholz explores how context, precision, and physiology converge to shape modern cardiovascular care. He opens with an editorial on "The Geography Gap," challenging the one-size-fits-all approach to cardiovascular risk models that ignore geographic variation in disease outcomes. Other featured studies in this issue include trials (OCEAN Mitral, PULSE), optimizing outcomes after transcatheter mitral repair, plus uncovering genetic links between placental malperfusion and congenital heart disease, evaluating CT angiography follow-up after left main PCI, and refining emergency triage with high-sensitivity troponin testing. Dr. Krumholz also speaks to editorials in this issue providing insight on the accompanying JACC articles, and a HeartBeat submission, with a reflection on balance and compassion in pediatric cardiology. Finally, he touches on our other JACC journal content, including new findings on blood groups and COVID-19 cardiovascular outcomes, and the first JACC: Basic to Translational Science Editor's page from the new editor-in-chief, Matthias Nahrendorf, MD, PhD, on the evolving landscape of translational science. This week in JACC highlights cardiology's movement toward more localized, integrated, and human-centered precision medicine.

Description Join host and Digital Education Committee Member, Danesh Kella, MBBS, FHRS and his guests Ratika Parkash, MD, MS, FHRS and Prashanthan Sanders, MBBS, PhD, FHRS at HRX Live 2025 in Atlanta, for this exciting discussion. The PRAGUE-25 trial, published in JACC in 2025, compared catheter ablation with a program of lifestyle modification plus antiarrhythmic drugs in obese patients (BMI 30–40 kg/m2) with symptomatic atrial fibrillation. At 12 months, freedom from atrial fibrillation was significantly higher with ablation (73%) than with lifestyle modification + AADs (35%), despite the latter group achieving greater weight loss and metabolic improvement. The findings suggest that while aggressive risk-factor control improves overall health, catheter ablation remains more effective for rhythm control in this population.    Learning Objectives Describe the comparative effectiveness of catheter ablation versus lifestyle modification with antiarrhythmic drug therapy in obese patients with symptomatic atrial fibrillation. Discuss how weight reduction and risk-factor modification influence atrial fibrillation outcomes, while recognizing that catheter ablation provides superior rhythm control despite metabolic improvements achieved through lifestyle intervention.   Article Authors Pavel Osmancik, Tomas Roubicek, Stepan Havranek, Jan Chovancik, Veronika Bulkova, Dalibor Herman, Martin Matoulek, Vladimir Tuka, Ivan Ranic, Jana Hozmanova, Marek Hozman, Lucie Znojilova, Adam Latinak, Jan Pidhorodecky, Milan Dusik, Jan Simek, Otakar Jiravsky, Bogna Jiravska-Godula, Frantisek Lehar, Michal Cernosek, Zuzana Hejdukova, Hana Zelinkova, Jiri Jarkovsky, and Klara Benesova  Podcast Contributors Prashanthan Sanders, MBBS, PhD, FHRS Danesh Kella, MBBS, FHRS Ratika Parkash, MD, MS, FHRS    All relevant financial relationships have been mitigated. Host Disclosure(s): D. Kella •Speaking/Teaching/Consulting: Zoll Medical Corporation, MBW Spectrum  ​Contributor Disclosure(s):    R. Parkash •Research: Abbott, Medtronic, Novartis • Membership on Advisory Committees: Medtronic  P. Sanders •Membership on Advisory Committees: Medtronic PLC, Pacemate, CathRx, Boston Scientific, Abbott Medical • Research: Abbott, Becton Dickinson, Calyan Technologies, Ceryx Medical, Biosense Webster, CathRx, HelloAlfred, Medtronic, Inc., Abbott Medical  Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner): S. Sailor: No relevant financial relationships with ineligible companies to disclose.

In this special episode of JACC This Week, Editor-in-Chief Dr. Harlan Krumholz introduces the November 4, 2025 issue, entirely devoted to hypertension and the landmark 2025 HAC Multi-Society High Blood Pressure Guideline. He discusses key updates—from reaffirming lower blood pressure targets and expanding out-of-office monitoring to integrating hypertension within the cardio-kidney-metabolic framework. Dr. Krumholz highlights expert commentaries covering policy, technology, therapeutics, and prevention, emphasizing how this forward-looking issue aims to move beyond publication toward true implementation. The episode calls for a cultural shift—making uncontrolled hypertension a "never event" through better systems, teamwork, and innovation.

The FiltrateJoel Topf @kidneyboy.bsky.social‬Swapnil Hiremath @hswapnil.medsky.socialNayan Arora captainchloride.bsky.socialSopia Ambruso @sophia-kidney.bsky.socialSpecial Guests Brendon Neuen @brendonneuen.bsky.social Associate Professor and Program Lead, Renal and Metabolic at The George Institute for Global Health. Nephrologist and Director of Kidney Trials at Royal North Shore Hospital.Neuen has had three prior appearances on Freely Filtered: EMPA Kidney, DUPLEX and Sparsentan in FSGS, FLOW and SemaglutideMuthiah Vaduganathan @mvaduganathan on X. Cardiologist at Brigham and Women's Hospital and Harvard Medical School. Assistant Professor of Medicine.Editing byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesDONATE to NephJC! Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes NEJM | NephJC SummaryFIDELIO Bakris et al, NEJM 2020 | NephJC Summary; subgroup throws doubt on efficacy of finerenone in patients on flozinsFIGARO Pitt et al, NEJM 2021; subgroups clearly shows finerenone works, flozins or notNEJM editorial (wrongly) saying do not use Flozins unless on RASi Don't use dual RAS blockade ONTARGET Yusuf et al, NEJM 2008; VA NEPHRON-D Fried et al NEJM 2013Why we cannot study finerenone in HFrEF (RALES Pitt et al NEJM 1999) Muthu is jealous of GFR slope and albuminuria surrogate endpoints and wants to borrow them for HFpEF (Inker et al EHJ 2025)Combination therapy and CV outcomes in hypertension (Wang et al JAMA Card 2024 on low dose combinations and BP; Egan et al Blood Pressure 2022 review of topic) CONFIRMATION HF trial registry entry (Finerenone and Empagliflozin in hospitalized patients with HF)23:20: Nayan and Swap miss a chance to say ‘de-flozination' to discuss stopping a flozin which would allow a patient to be included in the trial Finerenone is a CYP3A4 substrate (Heinig et al Clin Pharmacokinetics 2023); Useful list of CYP3A4 inducers and inhibitors Everyone should get an ABPM (Bugeja et al CMAJ 2022)EASiKIDNEY study design Albuminuria mediates CKD benefits with Finerenone (Agarwal et al Ann Intern Med 2023)GFR slope and Albuminuria and the FDA (Taylor et al eClin Med 2025) Dapagliflozin and Eplerenone combination crossover trial (Provenzano et al JASN 2022)Joel gets promoted! (PBFluids reflection) Bluesky NephJC Chat discussion on ‘renal remission' Withdrawal of Finerenone and worse outcomes from FINEARTS (Vaduganathan et al JACC 2025)Combination therapies Analysis from Brendan and Muthu (Neuen et al Circulation 2024)Do not use KFRE when GFR > 60 (KDIGO Practice Point 2.2.4: Note that risk prediction equations developed for use in people with CKD G3–G5, may not be valid for use in those with CKD G1–G2) Finerenone vs Spironolactone trial in Primary Aldosteronism (Hu et al Circulation 2025)FIND CKD trial design (Heerspink et al NDT 2025) FINE-ONE trial design (Heerspink et al Diab Res Practice 2023) Tubular SecretionsNayan keeping his chin up as Yankees lose and Mariners follow (MLB Playoffs)Sophia's adventures with Beekeeping (Royal Jelly?) Brendon loves listening to ‘Susan' by Raye Muthu is back into Taekwondo Swap is still reading Martha Wells (Witch King on GoodReads)Joel will be hiking the Laugavegur trail in Iceland

Dr. Harlan Krumholz introduces a JACC issue unified around the question of how low to target blood pressure, highlighting growing evidence that aiming near 120 mm Hg improves cardiovascular outcomes without harming quality of life. Several studies from the STEP and ESPRIT trials show that intensive blood pressure control widens retinal arterioles, lowers stroke risk, enhances well-being, and remains safe even in older adults. Long-term follow-up data demonstrate that early initiation of intensive therapy provides lasting cardiovascular protection, while new analyses using the PREVENT equations confirm that higher-risk patients gain the most absolute benefit. The issue underscores that intensive control is both safe and effective, and that the next challenge is implementing these proven strategies consistently in clinical practice.